Ritonavir: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='340' side='right' caption='Ritonavir, better known as Norvir, ([[1hxw]])' scene='Ritonavir/Ritonavir/1'> | ||
===Better Known as: Norvir (Kaletra when used in combination with Lopinavir)=== | ===Better Known as: Norvir (Kaletra when used in combination with Lopinavir)=== | ||
* Marketed By: Abbott | * Marketed By: Abbott Laboratories<br /> | ||
* Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | * Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 1996 (2013) <br /> | * Date of FDA Approval (Patent Expiration): 1996 (2013) <br /> | ||
* 2009 Sales: $310 Million | * U.S. 2009 Sales: $310 Million | ||
* Importance: It is a powerful [[HIV Protease]] inhibitor. It is a major component of most HIV combination therapies because of its potent inhibition capacity of CYP3A4, increasing the bioavailability of other viral inhibitors. | * Importance: It is a powerful [[HIV Protease]] inhibitor. It is a major component of most HIV combination therapies because of its potent inhibition capacity of CYP3A4, increasing the bioavailability of other viral inhibitors. | ||
* | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders. | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
When [[HIV]] infects a host, it directs the synthesis of several polyproteins. The maturation of the virus to its infectious form requires that these polyproteins be cleaved to their component proteins by [[HIV Protease]]. The subunits of <scene name='Ritonavir/Prot/3'>HIV Protease</scene> come together to form a catalytic tunnel capable of binding the nascent peptides and cleaving them into their mature form. Buried within this tunnel lies <scene name='Ritonavir/Cat/1'>two Asp-Thr-Gly conserved sequences</scene>, which contain the <scene name='Ritonavir/Cat/2'>catalytic Asp residues</scene>. These catalytic Asp residues carry out the hydrolytic cleavage of the viral polyproteins. | When [[HIV]] infects a host, it directs the synthesis of several polyproteins. The maturation of the virus to its infectious form requires that these polyproteins be cleaved to their component proteins by [[HIV Protease]]. The subunits of <scene name='Ritonavir/Prot/3'>HIV Protease</scene> come together to form a catalytic tunnel capable of binding the nascent peptides and cleaving them into their mature form. Buried within this tunnel lies <scene name='Ritonavir/Cat/1'>two Asp-Thr-Gly conserved sequences</scene>, which contain the <scene name='Ritonavir/Cat/2'>catalytic Asp residues</scene>. These catalytic Asp residues carry out the hydrolytic cleavage of the viral polyproteins. Ritonavir <scene name='Ritonavir/Cat/3'>binds very precisely</scene> to these conserved sequences within the HIV Protease tunnel, preventing the nascent polyproteins from entering. Unable to actively cleave the nascent proteins into their functional form, HIV is unable to mature and proliferate, allowing the patients immune system to fight off the infection more easily.<ref>PMID:1799632</ref><ref>PMID:17243183</ref> | ||
Despite its ability to inhibit HIV Protease, Ritonavir is primarily used in combination therapies to inhibit the metabolizing enzyme, <scene name='Ritonavir/Ritonavir_cyp/2'>cytochrome P4503A4</scene> (CYP3A4). Ritonair binds with <scene name='Ritonavir/Ritonavir_c/2'>high affinity to CYP3A4</scene>, inhibiting it. Since it is this enzyme which is responsible for metabolizing the other HIV Protease inhibitors, Ritonavir's inhibition of CYP3A4 increases the bioavilaibility of other [[Pharmaceutical_Drugs#Treatments|antiviral medications]].<ref>PMID: 20937904</ref> | Despite its ability to inhibit HIV Protease, Ritonavir is primarily used in combination therapies to inhibit the metabolizing enzyme, <scene name='Ritonavir/Ritonavir_cyp/2'>cytochrome P4503A4</scene> (CYP3A4). Ritonair binds with <scene name='Ritonavir/Ritonavir_c/2'>high affinity to CYP3A4</scene>, inhibiting it. Since it is this enzyme which is responsible for metabolizing the other HIV Protease inhibitors, Ritonavir's inhibition of CYP3A4 increases the bioavilaibility of other [[Pharmaceutical_Drugs#Treatments|antiviral medications]].<ref>PMID: 20937904</ref> | ||
| Line 16: | Line 17: | ||
===Drug Resistance=== | ===Drug Resistance=== | ||
The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]] | The biggest difficulty with treating [[HIV]] is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to [[HIV Protease]], See: [[HIV Protease Inhibitor Resistance Profile]] | ||
</StructureSection> | |||
===See Also=== | |||
* The page [[Molecular Playground/HIV Protease Inhibitor]] summarizes the history of AIDS before Ritonavir and the impact of Ritonavir and other [[HIV protease]] inhibitors. | |||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | |||
<tr> | |||
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset"> | |||
<div style="height:100%; width: 100%"> | |||
{{:HIV Protease Inhibitor Pharmacokinetics}} | |||
</div> | |||
</td> | |||
</tr> | |||
</table> | |||
===References=== | ===References=== | ||